AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21420176 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (untreated)
Number of subjects: 24
Study 18310181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 66
Study 18310181 — intervention group
Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 66
Study 16586388 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (200 mg 3 times daily for 3 days)
Number of subjects: 25
Study 14959882 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 percent hydrogen peroxide gel strip (Crest Whitestrips Supreme)
Number of subjects: 38
Study 14959882 — intervention group
Group type: COMPARATOR
Intervention: 6 percent hydrogen peroxide whitening strip (Crest Whitestrips)
Number of subjects: 38
Study 11474820 — intervention group
Group type: EXPERIMENTAL
Intervention: Bach-flower remedies
Number of subjects: 55
Study 11474820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 9187023 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UH)
Number of subjects: 0
Study 9187023 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) intravenous (iv)
Number of subjects: 0
Study 9187023 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) subcutaneous (sc)
Number of subjects: 0
Study 9187023 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine sulphate (PS)
Number of subjects: 0
Study 8387806 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindoprilat (1 mg over six hours)
Number of subjects: 36
Study 8387806 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (1.5 mg over six hours)
Number of subjects: 36
Study 8387806 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo (saline)
Number of subjects: 36
Study 3544631 — intervention group
Group type: EXPERIMENTAL
Intervention: nadolol 80 mg/day
Number of subjects: 20
Study 3544631 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 30203640 — intervention group
Group type: EXPERIMENTAL
Intervention: Circaid Juxtalite® adjustable compression wrap
Number of subjects: 30
Study 30203640 — intervention group
Group type: COMPARATOR
Intervention: 15-20 mmHg compression stockings (CS)
Number of subjects: 30
Study 25854500 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstruction with hamstrings tendon graft
Number of subjects: 32
Study 25854500 — intervention group
Group type: COMPARATOR
Intervention: ACL conservative treatment
Number of subjects: 32
Study 25033066 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (40 mg daily for subjects > 50 kg, 20 mg for 30‐50 kg, 10 mg for 20‐30 kg)
Number of subjects: 40
Study 25033066 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 40
Study 22735163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Diet (ID)
Number of subjects: 25
Study 22735163 — intervention group
Group type: COMPARATOR
Intervention: Continuous Diet (CD)
Number of subjects: 25
Study 19752153 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard KPP
Number of subjects: 32
Study 19752153 — intervention group
Group type: EXPERIMENTAL
Intervention: KPP with homolateral leg extension
Number of subjects: 32
Study 19752153 — intervention group
Group type: EXPERIMENTAL
Intervention: KPP with a wobble board and homolateral leg extension
Number of subjects: 32
Study 19752153 — intervention group
Group type: EXPERIMENTAL
Intervention: One-handed KPP
Number of subjects: 32
Study 19752153 — intervention group
Group type: EXPERIMENTAL
Intervention: KPP with heterolateral leg extension
Number of subjects: 32
Study 19752153 — intervention group
Group type: EXPERIMENTAL
Intervention: KPP with a wobble board
Number of subjects: 32
Study 19752153 — intervention group
Group type: EXPERIMENTAL
Intervention: KPP with one hand
Number of subjects: 32
Study 18682623 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine mesylate (PM)
Number of subjects: 484
Study 18682623 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 484
Study 15875530 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene (30 mg daily for 1 week)
Number of subjects: 19
Study 15875530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 12885710 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified fish sauce (10 mL containing 10 mg Fe as NaFeEDTA)
Number of subjects: 152
Study 11143915 — intervention group
Group type: EXPERIMENTAL
Intervention: Harpagophytum 2,610 mg per day
Number of subjects: 122
Study 11143915 — intervention group
Group type: COMPARATOR
Intervention: Diacerhein 100 mg per day
Number of subjects: 122
Study 9051279 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-focused intervention for widowers (N = 23)
Number of subjects: 46
Study 9051279 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-focused intervention for widows (N = 23)
Number of subjects: 46
Study 9051279 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control group (N = 59)
Number of subjects: 46
Study 8321613 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard feedback
Number of subjects: 49
Study 8321613 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-temperature biofeedback
Number of subjects: 49
Study 8321613 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study 3523330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical prostaglandin E2 gel
Number of subjects: 30
Study 3523330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31315471 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Holter ECG monitoring (EPM) for 10 days after the event, and at 3 and 6 months
Number of subjects: 281
Study 31315471 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SoC) 24h ECG monitoring
Number of subjects: 281
Study 28723914 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalazatide 30 mcg/dose
Number of subjects: 24
Study 28723914 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalazatide 60 mcg/dose
Number of subjects: 24
Study 28723914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26496265 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone (1800 mg per day) + NAC (1800 mg per day)
Number of subjects: 76
Study 26496265 — intervention group
Group type: COMPARATOR
Intervention: Placebo + NAC (1800 mg per day)
Number of subjects: 76
Study 24617160 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 128
Study 24617160 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water bottle
Number of subjects: 128
Study 21884870 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose
Number of subjects: 13608
Study 21884870 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 150 mg
Number of subjects: 13608
Study 21884870 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel 10 mg
Number of subjects: 13608
Study 19604522 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index (LGI) diet
Number of subjects: 38
Study 19604522 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic index (HGI) diet
Number of subjects: 38
Study 16770210 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical resection of lumbar juxta facet cysts
Number of subjects: 31
Study 16770210 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 31
Study 15585770 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc doses of 2.2 mg
Number of subjects: 8
Study 15585770 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc doses of 5.2 mg
Number of subjects: 8
Study 15585770 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc doses of 10.4 mg
Number of subjects: 8
Study 15585770 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc doses of 15.2 mg
Number of subjects: 8
Study 15585770 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc doses of 20.3 mg
Number of subjects: 8
Study 15585770 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc doses of 30.1 mg
Number of subjects: 8
Study 11736882 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (50 mg)
Number of subjects: 6
Study 11736882 — intervention group
Group type: EXPERIMENTAL
Intervention: CDCA (600 mg)
Number of subjects: 6
Study 11736882 — intervention group
Group type: COMPARATOR
Intervention: Control (nitrendipine 10 mg without bile acids)
Number of subjects: 6
Study 9596304 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg
Number of subjects: 159
Study 9596304 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg
Number of subjects: 159
Study 9596304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 9596304 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg and 800 microg
Number of subjects: 159
Study 7835324 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw potato starch (RPS) 50 g
Number of subjects: 7
Study 7835324 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn flakes (CF) 100 g
Number of subjects: 7
Study 7835324 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylon VII high amylomaize starch (HAS) 75 g
Number of subjects: 7
Study 7835324 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylon VII high amylomaize starch (HRA) 25 g
Number of subjects: 7
Study 7835324 — intervention group
Group type: COMPARATOR
Intervention: Lactulose (10 g)
Number of subjects: 7
Study 7835324 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran and oat bran (controls)
Number of subjects: 7
Study 7835324 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of RPS for 3 weeks
Number of subjects: 7
Study 7835324 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of HAS for 3 weeks
Number of subjects: 7
Study 2964327 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol 50mg three times daily for 4 weeks
Number of subjects: 33
Study 2964327 — intervention group
Group type: COMPARATOR
Intervention: Miglitol (0, 50, 100, 150, or 200mg)
Number of subjects: 33
Study 30129411 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab (IV) in Study 201 and OLE (bapi/bapi)
Number of subjects: 194
Study 30129411 — intervention group
Group type: COMPARATOR
Intervention: Placebo in Study 201 and bapineuzumab IV in OLE (placebo/bapi)
Number of subjects: 194
Study 30129411 — intervention group
Group type: COMPARATOR
Intervention: Bapineuzumab (SC) and placebo SC
Number of subjects: 194
Study 30129411 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab (IV)
Number of subjects: 194
Study 28075147 — intervention group
Group type: COMPARATOR
Intervention: Activity
Number of subjects: 181
Study 28075147 — intervention group
Group type: COMPARATOR
Intervention: Diet & Activity
Number of subjects: 181
Study 28075147 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 181
Study 26252343 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Test (6MWT)
Number of subjects: 85
Study 26252343 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental Shuttle Walk Test (ISWT)
Number of subjects: 85
Study 22671278 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% dimethyl sulfoxide-frozen autologous platelets (CPPs)
Number of subjects: 0
Study 22671278 — intervention group
Group type: COMPARATOR
Intervention: Fresh autologous platelets (Control)
Number of subjects: 0
Study 25572758 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week yoga program
Number of subjects: 40
Study 19675034 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscalpel-needle percutaneous release (group A)
Number of subjects: 83
Study 19675034 — intervention group
Group type: COMPARATOR
Intervention: Steroid injection (group B)
Number of subjects: 83
Study 16311070 — intervention group
Group type: COMPARATOR
Intervention: Serum digoxin concentration (SDC) ≥1.2 ng/ml
Number of subjects: 1366
Study 16311070 — intervention group
Group type: COMPARATOR
Intervention: Serum digoxin concentration (SDC) 0.5-1.1 ng/ml
Number of subjects: 1366
Study 16311070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1366
Study 16311070 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum digoxin concentration (SDC) 0.5-1.1 ng/ml in women with EF <35%
Number of subjects: 1366
Study 16311070 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum digoxin concentration (SDC) 0.5-1.1 ng/ml in women with EF ≥35%
Number of subjects: 1366
Study 15309451 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene tablets
Number of subjects: 18
Study 15309451 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato soup
Number of subjects: 18
Study 15309451 — intervention group
Group type: COMPARATOR
Intervention: Tomato juice
Number of subjects: 18
Study 11576930 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with supraphysiological doses of folic acid and vitamins B(6) and B(12)
Number of subjects: 4000
Study 11576930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000
Study 9244210 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ramipril (0.625 mg daily)
Number of subjects: 120
Study 9244210 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose ramipril (1.25 mg titrated to 10 mg/d)
Number of subjects: 120
Study 9244210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 7826445 — intervention group
Group type: EXPERIMENTAL
Intervention: CME program including interactive small-group discussion, role playing, videotaped clinical encounters, lecture presentations, and trigger tapes
Number of subjects: 57
Study 7826445 — intervention group
Group type: EXPERIMENTAL
Intervention: CME program
Number of subjects: 57
Study 7826445 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-participating physicians)
Number of subjects: 57
Study 2244446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (200 mg IV)
Number of subjects: 7
Study 2244446 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (20 mg IV)
Number of subjects: 7
Study 357097 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 10
Study 357097 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol sulfate
Number of subjects: 10
Study 357097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31982963 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB)
Number of subjects: 46
Study 31982963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 30058959 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg bid plus acetylsalicylic acid 100 mg
Number of subjects: 1905
Study 30058959 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg bid
Number of subjects: 1905
Study 30058959 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid 100 mg per day
Number of subjects: 1905
Study 28422300 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin LD 80 mg
Number of subjects: 145
Study 28422300 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin LD 40 mg
Number of subjects: 145
Study 28422300 — intervention group
Group type: COMPARATOR
Intervention: No statin LD (control group)
Number of subjects: 145
Study 28422300 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose statins (subgroup analysis)
Number of subjects: 145
Study 25357145 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous conditioned plasma (ACP) injections
Number of subjects: 52
Study 25357145 — intervention group
Group type: COMPARATOR
Intervention: Low-level laser application
Number of subjects: 52
Study 24176201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine users
Number of subjects: 86
Study 24176201 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 86
Study 23289345 — intervention group
Group type: EXPERIMENTAL
Intervention: JCS‐01 focused ultrasound fat reduction machine treatment on the 1st and 7th days.
Number of subjects: 40
Study 23289345 — intervention group
Group type: COMPARATOR
Intervention: Control group with ultrasound energy turned off during treatments.
Number of subjects: 40
Study 20083961 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 102
Study 20083961 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 102
Study 20083961 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 17340137 — intervention group
Group type: EXPERIMENTAL
Intervention: MDR1 and BCRP mRNA expression
Number of subjects: 154
Study 17340137 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BCRP mRNA
Number of subjects: 154
Study 17340137 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34-related MDR1/BCRP coexpression
Number of subjects: 154
Study 16256784 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment during cardiopulmonary bypass
Number of subjects: 381
Study 16256784 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment during cardiopulmonary bypass
Number of subjects: 381
Study 16256784 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 381
Study 16256784 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 381
Study 11867394 — intervention group
Group type: EXPERIMENTAL
Intervention: Trachlight
Number of subjects: 148
Study 11867394 — intervention group
Group type: COMPARATOR
Intervention: Fastrach
Number of subjects: 148
Study 10218737 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil (50 mg, titrated to 100 mg)
Number of subjects: 48
Study 10218737 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (20 mg, titrated to 2 x 20 mg)
Number of subjects: 48
Study 8730975 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 50 mg
Number of subjects: 8
Study 8730975 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 100 mg
Number of subjects: 8
Study 8730975 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg
Number of subjects: 8
Study 8730975 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 600 mg
Number of subjects: 8
Study 8730975 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 900 mg
Number of subjects: 8
Study 8730975 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of xanthine oxidase
Number of subjects: 8
Study 8730975 — intervention group
Group type: EXPERIMENTAL
Intervention: 1MU/1MX ratio
Number of subjects: 8
Study 8730975 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxypurinol concentration for inhibition of xanthine oxidase
Number of subjects: 8
Study 1858727 — intervention group
Group type: EXPERIMENTAL
Intervention: H influenzae b oligosaccharide‐CRM197 conjugate vaccine (3 doses)
Number of subjects: 171
Study 1858727 — intervention group
Group type: EXPERIMENTAL
Intervention: H influenzae b oligosaccharide‐CRM197 conjugate vaccine (2 doses) followed by H influenzae type b polysaccharide vaccine (1 dose)
Number of subjects: 171
Study 1858727 — intervention group
Group type: EXPERIMENTAL
Intervention: H influenzae b oligosaccharide‐CRM197 conjugate vaccine (1 dose) followed by H influenzae type b polysaccharide vaccine (2 doses)
Number of subjects: 171
Study 1858727 — intervention group
Group type: COMPARATOR
Intervention: H influenzae type b polysaccharide vaccine (as a second dose)
Number of subjects: 171
Study 6354385 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide
Number of subjects: 23
Study 6354385 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 23
Study 30794252 — intervention group
Group type: EXPERIMENTAL
Intervention: Microtextured implants with microgrooved collar design
Number of subjects: 58
Study 30794252 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow implant diameter
Number of subjects: 58
Study 30794252 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall implant survival
Number of subjects: 58
Study 28129499 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Education System
Number of subjects: 507
Study 28129499 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 507
Study 25393645 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide 20 μg
Number of subjects: 222
Study 25393645 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide 40 μg
Number of subjects: 222
Study 25393645 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide 80 μg
Number of subjects: 222
Study 25393645 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg
Number of subjects: 222
Study 25393645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 22383279 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management training (SMT)
Number of subjects: 70
Study 22383279 — intervention group
Group type: COMPARATOR
Intervention: Regular care condition (Control)
Number of subjects: 70
Study 21855560 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS over the left dorsolateral prefrontal cortex (LDLPFC) using 10-Hz pulses for 5- and 20-s intertrain intervals
Number of subjects: 90
Study 21855560 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS over the left dorsolateral prefrontal cortex (LDLPFC)
Number of subjects: 90
Study 19860834 — intervention group
Group type: EXPERIMENTAL
Intervention: apoNgb at pH 2.0
Number of subjects: 0
Study 19860834 — intervention group
Group type: COMPARATOR
Intervention: apoMb at pH 2.0
Number of subjects: 0
Study 19860834 — intervention group
Group type: EXPERIMENTAL
Intervention: Ngb
Number of subjects: 0
Study 16499744 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-directed care (NC) group
Number of subjects: 23
Study 16499744 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC) group
Number of subjects: 23
Study 14767164 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 16
Study 14767164 — intervention group
Group type: COMPARATOR
Intervention: Manual cross-brushing technique
Number of subjects: 16
Study 11704092 — intervention group
Group type: EXPERIMENTAL
Intervention: EE20/GSD75
Number of subjects: 18
Study 11704092 — intervention group
Group type: EXPERIMENTAL
Intervention: EE15/GSD60
Number of subjects: 18
Study 1316100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur.Uracil (UFT)
Number of subjects: 90
Study 1316100 — intervention group
Group type: COMPARATOR
Intervention: Tegafur (FT)
Number of subjects: 90